Licochalcone a Exhibits Leishmanicidal Activity in vitro and in Experimental Model of Leishmania ( Leishmania ) Infantum
The efficacy of Licochalcone A (LicoA) and its two analogs were reported against and , and in experimental model of . Initially, LicoA and its analogs were screened against promastigote forms of . LicoA was the most active compound, with IC values of 20.26 and 3.88 μM at 24 and 48 h, respectively. A...
Gespeichert in:
Veröffentlicht in: | Frontiers in veterinary science 2020-12, Vol.7, p.527-527 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The efficacy of Licochalcone A (LicoA) and its two analogs were reported against
and
, and in experimental model of
. Initially, LicoA and its analogs were screened against promastigote forms of
. LicoA was the most active compound, with IC
values of 20.26 and 3.88 μM at 24 and 48 h, respectively. Against amastigote forms, the IC
value of LicoA was 36.84 μM at 48 h. In the next step, the effectivity of LicoA was evaluated
against promastigote and amastigote forms of
. Results demonstrated that LicoA exhibited leishmanicidal activity
against promastigote forms with IC
values of 41.10 and 12.47 μM at 24 and 48 h, respectively; against amastigote forms the IC
value was 29.58 μM at 48 h. Assessment of cytotoxicity demonstrated that LicoA exhibited moderate mammalian cytotoxicity against peritoneal murine macrophages; the CC
value was 123.21 μM at 48 h and showed about 30% of hemolytic activity at concentration of 400 μM.
infected hamsters and treated with LicoA at 50 mg/kg for eight consecutive days was able to significantly reduce the parasite burden in both liver and spleen in 43.67 and 39.81%, respectively, when compared with negative control group. These findings suggest that chalcone-type flavonoids can be a promising class of natural products to be considered in the search of new, safe, and effective compounds capable to treat canine visceral leishmaniosis (CVL). |
---|---|
ISSN: | 2297-1769 2297-1769 |
DOI: | 10.3389/fvets.2020.00527 |